Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments



On Wednesday, Viatris Inc. (NASDAQ:VTRS) said it has inked a pact with Idorsia for a significant global research and development collaboration.

This partnership involves selatogrel, an innovative self-administered treatment for individuals with a background of acute myocardial infarction (AMI), also known as a heart attack. 

Under the deal, Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets and additional innovative assets in the future.

It leverages Viatris’ worldwide cardiovascular portfolio, along with its distribution prowess in self-administered therapies for critical acute conditions.

The partnership additionally encompasses …

Full story available on


Leave a Reply

Your email address will not be published. Required fields are marked *